ARUP's Laboratory Test Directory
| 0081326: Hepatocellular Carcinoma Tumor Marker Panel |
| Test Mnemonic: HEP CAR | |
|
Methodology: Liquid-Phase Binding Immunoassay
Performed: Refer to individual components Reported: 3-6 days |
| Specimen Required: | |
|
Collect: One 3 mL red or SST.
Transport: 1 mL serum at 2-8°C. (Min: 0.5mL) Submit specimen in an ARUP Standard Transport Tube. Pediatric Collection/Transport: 0.5 mL serum at 2-8°C. Submit specimen in an ARUP Standard Transport Tube. Remarks: Separate serum from cells ASAP. Avoid repeated freeze/thaw cycles. Unacceptable Conditions: Plasma Stability: After separation from cells: Ambient: 8 hours; Refrigerated: 1 week; Frozen: 3 months; |
|
| Reference Interval: | ||||||||||||
|
| Interpretive Data: | |
|
The Wako LiBASys method is used for these tests. Results obtained with different assay methods or kits cannot be used interchangeably. The AFP-L3% assay is intended as a risk assessment test for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated AFP-L3% values have been shown to be associated with a seven-fold increase in the risk of developing hepatocellular carcinoma within the next 21 months. Patients with elevated serum AFP-L3% should be more intensely evaluated for evidence of hepatocellular carcinoma. The result is not interpretable as a tumor marker in pregnant females. The des-gamma-carboxy Prothrombin (DCP) assay is intended as a risk assessment test for the development of hepatocellular carcinoma in patients with chronic liver diseases. Elevated DCP values have been shown to be associated with an increased risk of developing hepatocellular carcinoma. Patients with elevated serum DCP should be more intensely evaluated for evidence of hepatocellular carcinoma. |
| CPT Code(s): | |
| 82107 AFP L3; 86316 DCP |